Serra C, Giacopelli A
Respiration. 1986;50 Suppl 2:249-53. doi: 10.1159/000195138.
A group of patients suffering from chronic obstructive lung disease, selected according to clinical criteria and respiratory function, were treated daily for at least 84 days using a metered aerosol containing a combination of a beta 2-agonist (fenoterol) and an atropine-like drug (ipratropium bromide). Every 14 days, respiratory and cardiovascular function was measured and analysed statistically. Information was compiled daily by the patients themselves on dyspnoea, cough, peak flow, any increase in dosage over the recommended dose and any side-effects that might have developed. The results obtained demonstrated that the combination of fenoterol and ipratropium bromide produced clear improvements in respiratory function and symptomatology throughout the observation period. The drug was well tolerated by the majority of patients.
一组根据临床标准和呼吸功能挑选出的慢性阻塞性肺疾病患者，每天使用一种含有β2受体激动剂（非诺特罗）和一种类阿托品药物（异丙托溴铵）组合的定量气雾剂进行治疗，疗程至少84天。每14天测量呼吸和心血管功能，并进行统计学分析。患者本人每天记录呼吸困难、咳嗽、峰值流量、超过推荐剂量的任何剂量增加以及可能出现的任何副作用。所得结果表明，在整个观察期内，非诺特罗和异丙托溴铵的组合使呼吸功能和症状有明显改善。大多数患者对该药物耐受性良好。
